Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Research Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.
Front Cell Infect Microbiol. 2024 Apr 29;14:1356542. doi: 10.3389/fcimb.2024.1356542. eCollection 2024.
This study aimed to investigate the possible prognostic significance of interferon alpha-beta receptor subunit 2 (IFNAR2) and tyrosine kinase 2 (TYK2) expressions.
We conducted a retrospective study including COVID-19 adult patients. All blood samples were collected before any interventions. The expressions of IFNAR2 and TYK2 were assessed using real-time PCR in venous blood samples of 54 cases and 56 controls. The transcript quantities of IFNAR2 and TYK2 genes were assessed using a Delta-Ct method.
Our findings show no significant differences in gene expression levels for IFNAR2 and TYK2 between patients who required oxygen (O2) therapy and those who did not (p-value = 0.732 and p-value = 0.629, respectively). Likewise, there were no significant differences in IFNAR2 and TYK2 expressions between patients hospitalized for less than 7 days and those hospitalized for 7 days or more (p-value = 0.455 and p-value = 0.626, respectively). We also observed a weak correlation between IFNAR2 expression and CRP (p-value = 0.045, r = 0.192). There was a negative correlation between the expression levels of IFNAR2 and TYK2 transcripts in COVID-19 patients (p-value = 0.044; partial correlation coefficient = -0.283). Additionally, IFNAR2 and TYK2 were significantly downregulated in the COVID-19 group compared to healthy subjects (p-value = 0.002 and p-value = 0.028, respectively). However, neither IFNAR2 nor TYK2 expression was significantly different between the case subgroups based on COVID-19 severity. The IFNAR2 ΔΔCt (B = -0.184, 95% CI: -0.524-0.157, p-value = 0.275) and the TYK2 ΔΔCt (B = 0.114, 95% CI: -0.268-0.496, p-value = 0.543) were not found to be significant predictors of hospitalization duration. The area under the curve (AUC) for IFNAR2 expression is 0.655 (p-value = 0.005, 95% CI: 0.554-0.757), suggesting its poor discriminative value.
We were unable to comment definitively on the prognostic power of IFNAR2 and TYK2 expressions in COVID-19 patients, and larger-scale studies are needed. The principal limitations of this study included the lack of longitudinal analysis and limited sample size.
本研究旨在探讨干扰素α-β受体亚基 2（IFNAR2）和酪氨酸激酶 2（TYK2）表达的可能预后意义。
我们进行了一项回顾性研究，纳入了 COVID-19 成年患者。所有血液样本均在任何干预措施之前采集。使用实时 PCR 检测 54 例病例和 56 例对照静脉血样本中的 IFNAR2 和 TYK2 表达。使用 Delta-Ct 法评估 IFNAR2 和 TYK2 基因的转录量。
我们的研究结果显示，需要氧疗和不需要氧疗的患者之间 IFNAR2 和 TYK2 的基因表达水平没有显著差异（p 值分别为 0.732 和 0.629）。同样，住院时间少于 7 天和住院时间为 7 天或更长时间的患者之间 IFNAR2 和 TYK2 的表达也没有显著差异（p 值分别为 0.455 和 0.626）。我们还观察到 IFNAR2 表达与 CRP 之间存在弱相关性（p 值 = 0.045，r = 0.192）。COVID-19 患者中 IFNAR2 和 TYK2 转录本的表达水平呈负相关（p 值 = 0.044；偏相关系数 = -0.283）。此外，与健康对照组相比，IFNAR2 和 TYK2 在 COVID-19 组中显著下调（p 值分别为 0.002 和 0.028）。然而，根据 COVID-19 严重程度，IFNAR2 和 TYK2 的表达在病例亚组之间没有显著差异。IFNAR2 ΔΔCt（B = -0.184，95%CI：-0.524-0.157，p 值 = 0.275）和 TYK2 ΔΔCt（B = 0.114，95%CI：-0.268-0.496，p 值 = 0.543）均未发现是住院时间的显著预测因子。IFNAR2 表达的曲线下面积（AUC）为 0.655（p 值 = 0.005，95%CI：0.554-0.757），表明其鉴别价值较差。
我们无法对 COVID-19 患者 IFNAR2 和 TYK2 表达的预后能力做出明确评价，需要进行更大规模的研究。本研究的主要局限性包括缺乏纵向分析和样本量有限。
Zotero 插件
